Literature DB >> 33603877

Heterogeneity of antigenic constellation in human hepatocellular carcinoma.

Mihai Ceausu1, Bogdan Socea2,3, Dragos Serban2,4, Cătălin Gabriel Smarandache2,4, Dragoş Predescu2,5, Nicolae Bacalbaşa6,7, Iulian Slavu8, Adrian Tulin8,9, Lucian Alecu2,8, Zenaida Ceauşu10.   

Abstract

Hepatocellular carcinoma is one of the primary liver malignancies responsible for over a million deaths per year worldwide (approximately 10% of all deaths in the adult age range). The diagnosis of HCC can be difficult and often requires the use of more than one microscopic technique. A retrospective study was performed on a study batch of 42 cases that died of HCC due to metastasis or other secondary complications. Tissue samples were taken in order to investigate the tumour antigenic constellation by means of IHC method using a large variety of antibodies. In situ hybridization was also performed for albumin mRNA to assess the albumin expression in some selected cases. Telomerase activity was investigated using IHC method for the hTERT catalytic subunit. A cocktail of hepatic cytokeratins (CK8, 18) combined with Hep Par-1 and associated to albumin proved to be more powerful than albumin alone in differentiating HCC and increased the value of tumour diagnosis. hTERT expression was proportionally reverse to the tumour degree of differentiation, but was independent from the expression of tumour-proliferating indexes. The heterogeneity of the antigenic constellation in hepatocellular carcinoma suggests an antigenic mosaicism, which can be expressed a synchronous or metachronous manner, depending on the tumour degree of differentiation.
Copyright © 2020, Spandidos Publications.

Entities:  

Keywords:  antigenic mosaicism; hepatocellular carcinoma; histopathologic variability; immunophenotypical heterogeneity; molecular pathology

Year:  2021        PMID: 33603877      PMCID: PMC7851646          DOI: 10.3892/etm.2021.9701

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  24 in total

1.  Branched chain in situ hybridization for albumin as a marker of hepatocellular differentiation: evaluation of manual and automated in situ hybridization platforms.

Authors:  Mohammad Shahid; Aysha Mubeen; Julie Tse; Sanjay Kakar; Adrian C Bateman; Darrell Borger; Miguel N Rivera; David T Ting; Vikram Deshpande
Journal:  Am J Surg Pathol       Date:  2015-01       Impact factor: 6.394

2.  Utilization of antihepatocyte clone OCH1E5 (Hep Par 1) in histological evaluation of liver tumors.

Authors:  A D Amarapurkar; J D Rege; A S Joshi; K Vaiphei; D N Amarapurkar
Journal:  Indian J Pathol Microbiol       Date:  2006-07       Impact factor: 0.740

3.  Evaluation and comparison of microvessel density using the markers CD34 and CD105 in regenerative nodules, dysplastic nodules and hepatocellular carcinoma.

Authors:  Vanderlei Segatelli; Ebe Christie de Oliveira; Ilka F S F Boin; Elaine Cristina Ataide; Cecilia Amelia F Escanhoela
Journal:  Hepatol Int       Date:  2014-03-02       Impact factor: 6.047

4.  Hep par 1 antibody stain for the differential diagnosis of hepatocellular carcinoma: 676 tumors tested using tissue microarrays and conventional tissue sections.

Authors:  Zhen Fan; Matt van de Rijn; Kelli Montgomery; Robert V Rouse
Journal:  Mod Pathol       Date:  2003-02       Impact factor: 7.842

5.  Immunoreactivity of Hep Par 1 in hepatic and extrahepatic tumors and its correlation with albumin in situ hybridization in hepatocellular carcinoma.

Authors:  Sanjay Kakar; Trudie Muir; Linda M Murphy; Ricardo V Lloyd; Lawrence J Burgart
Journal:  Am J Clin Pathol       Date:  2003-03       Impact factor: 2.493

6.  [Expression and significance of hTERT, c-myc and Ki-67 in hepatocellular carcinoma].

Authors:  Yong-wei Fang
Journal:  Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi       Date:  2009-04

7.  Comparative immunohistochemical profile of hepatocellular carcinoma, cholangiocarcinoma, and metastatic adenocarcinoma.

Authors:  Sean K Lau; Sonam Prakash; Stephen A Geller; Randa Alsabeh
Journal:  Hum Pathol       Date:  2002-12       Impact factor: 3.466

Review 8.  Best practices in diagnostic immunohistochemistry: hepatocellular carcinoma versus metastatic neoplasms.

Authors:  Sanjay Kakar; Allen M Gown; Zachary D Goodman; Linda D Ferrell
Journal:  Arch Pathol Lab Med       Date:  2007-11       Impact factor: 5.534

9.  Distinction of hepatocellular carcinoma from benign hepatic mimickers using Glypican-3 and CD34 immunohistochemistry.

Authors:  Wanda M P Coston; Sofia Loera; Sean K Lau; Shin Ishizawa; Zhong Jiang; Chin-Lee Wu; Yun Yen; Lawrence M Weiss; Peiguo G Chu
Journal:  Am J Surg Pathol       Date:  2008-03       Impact factor: 6.394

Review 10.  Hepatocellular carcinoma: a review of diagnostic challenges for the pathologist.

Authors:  Alberto Quaglia
Journal:  J Hepatocell Carcinoma       Date:  2018-11-08
View more
  4 in total

1.  Impact of COVID-19 pandemic on clinicopathological features of transplant recipients with hepatocellular carcinoma: A case-control study.

Authors:  Sami Akbulut; Tevfik Tolga Sahin; Volkan Ince; Sezai Yilmaz
Journal:  World J Clin Cases       Date:  2022-05-26       Impact factor: 1.534

2.  Extrahepatic Disease in Hepatocellular Carcinoma: Do We Always Need Whole-Body CT or Is Liver MRI Sufficient? A Subanalysis of the SORAMIC Trial.

Authors:  Thomas Geyer; Philipp M Kazmierczak; Ingo G Steffen; Peter Malfertheiner; Bora Peynircioglu; Christian Loewe; Otto van Delden; Vincent Vandecaveye; Bernhard Gebauer; Maciej Pech; Christian Sengel; Irene Bargellini; Roberto Iezzi; Alberto Benito; Christoph J Zech; Antonio Gasbarrini; Kerstin Schütte; Jens Ricke; Max Seidensticker
Journal:  Biomedicines       Date:  2022-05-18

Review 3.  Contrast-Enhanced Ultrasound for Monitoring Treatment Response in Different Stages of Hepatocellular Carcinoma.

Authors:  Mariella Faccia; Matteo Garcovich; Maria Elena Ainora; Laura Riccardi; Maurizio Pompili; Antonio Gasbarrini; Maria Assunta Zocco
Journal:  Cancers (Basel)       Date:  2022-01-18       Impact factor: 6.639

4.  Automatically Extracted Machine Learning Features from Preoperative CT to Early Predict Microvascular Invasion in HCC: The Role of the Zone of Transition (ZOT).

Authors:  Matteo Renzulli; Margherita Mottola; Francesca Coppola; Maria Adriana Cocozza; Silvia Malavasi; Arrigo Cattabriga; Giulio Vara; Matteo Ravaioli; Matteo Cescon; Francesco Vasuri; Rita Golfieri; Alessandro Bevilacqua
Journal:  Cancers (Basel)       Date:  2022-04-03       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.